- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05093374
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neovascular age-related macular degeneration (nAMD) is a significant burden to health care systems in industrialized countries. Due to its chronic nature, continuous follow-up and treatment is needed to prevent significant loss of visual function in patients with nAMD.
Vascular endothelial growth factor (VEGF) plays a major role in the pathomechanisms of nAMD and large multicenter trials have shown that intravitreal application of substances which intercept the VEGF pathway can interrupt the progression of nAMD and improve the visual outcome.
As every single injection bears the risk of sight-threatening complications and increases the financial burden to health care providers, several studies have tested different treatment regimens, to decrease the number of applicated injections without compromising the gains in visual acuity. Thereby, strict protocols have been compared to flexible "as needed" regimens (pro re nata, PRN) and regimens with proactive increments of injection intervals (treat and extend, T&E).
Studies have indicated that the outcome of anti-VEGF treatment is better in standardized clinical trials than in so-called "real world settings". This is explained by tight exclusion criteria of sponsored trials, the shorter follow-up time and the small number of patients that are treated per center, resulting in a better standard of care.
PRN as well as T&E management showed disadvantages such as significant less vision gain in PRN and possible over treatment in T&E.
Recently, additional treatment criteria were described to improve the patients care.
Advances in diagnostic precision by SD-OCT using automated algorithms to accurately measure fluid volumes in all compartments are solid tools to determine disease activity. They allow to precisely quantifying the impact of therapeutic parameters on disease activity.
Multicenter study analyses have shown that the amount of intraretinal fluid has a significant effect on vision outcome. Subretinal fluid or Pigmentepithelial detachment have been described to be less important. These findings were the basis for designing an efficient point-of-care management. Automated quantification of the fluid amount using artificial intelligence (AI) may serve as a reliable and objective method to determine the personalized point-of-care.
To prove the efficacy of point-of-care management, prospective studies in real-world settings are required. More data is required to assess the outcome of real-world settings and find ways to improve treatment results, when larger amounts of patients are treated and less resources are available for decision making.
The purpose of this study is to implement quantitative assessment tools for the treatment of neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Stefan Sacu, MD
- Phone Number: 79620 +43 1 40400
- Email: stefan.sacu@meduniwien.ac.at
Study Contact Backup
- Name: Ursula Schmidt-Erfurth, MD
- Phone Number: 79310 +43 1 40400
- Email: ursula.schmidt-erfurth@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Department of Ophthalmology, Medical University of Vienna, Austria
-
Principal Investigator:
- Stefan Sacu, Associate Professor, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Adults ≥ 50 years
- Active neovascular AMD (classic, occult choroidal neovascularization (CNV), RAP lesion or PCV lesion) assessed by OCT, OCTA, FA
- Patients who have a BCVA score better or equal 0.1 (20/200) in the study eye using ETDRS
- No significant fibrosis or geographic atrophy (GA) involving the fovea
- Willingness and ability to comply with study visits and study procedures
- Signed informed consent form
Exclusion Criteria
- Hypersensitivity to Fluoresceine, Ranibizumab, Aflibercept, Brolucizumab or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose)
- Any surgical treatment of the eye within 3 months prior to baseline in the study eye
- History of pseudophakic cystoid macular edema (Irvine Gass Syndrome)
- History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 0, or a history of post-operative complications within the last 12 months preceding Visit 0 in the study eye (uveitis, cyclitis etc.)
- History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio >0,9
- Aphakia in the study eye
- Presence of a retinal pigment epithelial tear involving the macula in the study eye
- Any concurrent intraocular condition in the study eye (e.g. advanced cataract or diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the twelve-month study period to prevent or treat visual loss that might result from that condition
- Active intraocular inflammation (grade trace or above) in the study eye
- Active or suspected ocular or periocular infection in the study eye
- Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye
- Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment
- Evidence of current infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
- Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery) during the study period
- Presence of corneal decompensation, haze or scaring with an impact on BCVA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 - Quantitative
Patients will undergo monthly follow-up visits including fluid quantification and will be retreated in case of active disease, which is defined as:
Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. |
All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented. Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF.
Other Names:
All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented. In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment.
Other Names:
|
Active Comparator: Cohort 2 - Qualitative
Patients will undergo monthly follow-up visits. Treatment will be performed in case of active disease, which is defined as:
In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment. |
All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented. Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF.
Other Names:
All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented. In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of injections
Time Frame: 12 months
|
Number of injections necessary within study period
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of injections Best-corrected visual acuity (BCVA) assessed by ETDRS Score
Time Frame: 12 months
|
Longitudinal changes within each group in ETDRS-BCVA and quantitative anatomic measurements in the macula assessed with noninvasive imaging
|
12 months
|
Macular fluid volumes
Time Frame: 12 months
|
Changes in total amount of fluid in nanoliters within the central millimeter assessed with automated quantitative fluid measurement on noninvasive OCT imaging.
|
12 months
|
Formation of geographic-like macular atrophy
Time Frame: 12 months
|
Formation of geographic-like macular atrophy assessed by fundus photography with specials filters
|
12 months
|
Formation of retinal tears
Time Frame: 12 months
|
Formation of retinal tears assessed by OCT
|
12 months
|
Chorioretinal perfusion
Time Frame: 12 months
|
Chorioretinal perfusion (OCTA, ICG)
|
12 months
|
Perfusion of the neovascular lesion
Time Frame: 12 months
|
Perfusion of the neovascular lesion (OCTA, FA and ICG, SS)
|
12 months
|
Quality of Life by Questionnaire
Time Frame: 12 months
|
Quality of Life assessed by Questionnaire NEI - VFQ 25
|
12 months
|
Central retinal thickness
Time Frame: 12 months
|
Measurement of central retinal thickness in micrometers on noninvasive OCT imaging
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stefan Sacu, MD, Medical University of Vienna, Dept. of Ophthalmology and Optometry
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1672_2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exudative Macular Degeneration
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
Wake Forest University Health SciencesModulightWithdrawnExudative Age Related Macular DegenerationUnited States
-
Hospital St. Joseph, Marseille, FranceUnknownExudative Age-Related Macular DegenerationFrance
-
Alcon ResearchCompletedExudative Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
-
Subhransu K. Ray, M.D., Ph.D.Bay Area Retina AssociatesCompletedExudative Age-Related Macular DegenerationUnited States
-
Hospital St. Joseph, Marseille, FranceUnknownMacular Degeneration Exudative Eye BilateralFrance
-
The Retina Center of St. Louis County, PCZeaVision, Inc.CompletedExudative Age-Related Macular DegenerationUnited States
-
Alcon ResearchCompletedExudative Age-Related Macular Degeneration
-
Alcon ResearchCompletedExudative Age-Related Macular Degeneration
Clinical Trials on anti-VEGF agent
-
Johns Hopkins UniversityTerminatedWet Macular Degeneration | Neovascular Age-related Macular Degeneration | Submacular HemorrhageUnited States
-
University of LeipzigUnknownDiabetic Macular Edema | Macular Edema | Retinal Vein OcclusionGermany
-
University of California, DavisUniversity of California, San FranciscoCompletedExudative Age-related Macular DegenerationUnited States
-
Shahid Beheshti University of Medical SciencesCompletedDiabetic Macular EdemaIran, Islamic Republic of
-
Peking University Third HospitalRecruitingProliferative Diabetic RetinopathyChina
-
Ruijin HospitalCompletedProliferative Diabetic Retinopathy | Neovascular GlaucomaChina
-
Centre Hospitalier Sud FrancilienCompletedRetinopathy of PrematurityFrance
-
Wenzhou Medical UniversityUnknownProliferative Diabetic Retinopathy | Vitrectomy | PRP | Anti-VEGF
-
BayerCompletedWet Macular DegenerationGermany
-
Eyetech PharmaceuticalsCompletedMacular Degeneration | Choroidal NeovascularizationUnited States